Collectively, in silico modeling has provided a means to generate novel heterodimeric ChEIs, but results described herein will need to be supported with laboratory compound synthesis and subsequent in vitro cholinesterase inhibitor validation assays before further pharmacokinetic and pharmacodynamic evaluation in vivo to assess their ability to mitigate cognitive decline in models of AD. This evidence concerns the gene BCHE and Alzheimer disease.